EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Use of lecanemab for the treatment of Alzheimer's disease: A systematic review

Md Fahad Hossain iD, Ashma Ul Husna, Manish Kharel

Brain and Behavior · 2024-06 · 14 (6)

DOI: 10.1002/brb3.3592 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Brain and Behavior, online erschienen am 12.06.2024. Verfasst von Md Fahad Hossain und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Health and Family Welfare, Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are currently accessible.

Method

Preferred Reporting Items for Systematic Reviews and Meta‐Analysis recommendations were followed. In order to find relevant studies on lecanemab, we carried out a thorough literature search utilizing the electronic databases MEDLINE via PubMed, Cochrane, Web of Science, EBSCOhost, and Scopus. Excluding any research using experimental animals, we looked at lecanemab's effectiveness and side effects in treating AD in human clinical trials. Three randomized controlled studies were included.

Findings

According to studies, lecanemab lessens clinical deterioration and reduces brain amyloid‐beta plaques (difference,.45; 95% confidence interval,.67 to.23; p < .001). Participants who received lecanemab saw a greater frequency of amyloid‐related imaging abnormalities (ARIA)‐H (17.3% vs. 9.0%) and ARIA‐E (12.6% vs. 1.7%), which is a significant adverse outcome.

Conclusion

Lecanemab has been shown to have an impact on the two primary pathophysiologic indicators of AD (Aβ and tau). There are still a lot of unresolved issues related to lecanemab. Future research on the effectiveness and safety of lecanemab is advised in order to determine that the advantages of this medication exceed the disadvantages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedHumansAmyloid beta-PeptidesBrainPlaque, Amyloid

Stichwörter der Autor:innen

Alzheimer'sLeqembilecanemab

Substanzen

Amyloid beta-PeptideslecanemabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Ministry of Health and Family Welfare, Dhaka, Bangladesh.
  • Mercy Health St. Elizabeth Youngstown Hospital, Youngstown, Ohio, USA.
  • Department of Medicine, Kathmandu Medical College, Kathmandu, Nepal.

ORCID-Profile: Md Fahad Hossain

Zitieren

APA

Hossain, M. F., Husna, A. U., & Kharel, M. (2024). Use of lecanemab for the treatment of Alzheimer's disease: A systematic review. Brain and Behavior, 14(6). https://doi.org/10.1002/brb3.3592

Vancouver

Hossain MF, Husna AU, Kharel M. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review. Brain and Behavior. 2024;14(6). doi:10.1002/brb3.3592

BibTeX
@article{Hossain2024,
  author = {Hossain, Md Fahad and Husna, Ashma Ul and Kharel, Manish},
  title = {Use of lecanemab for the treatment of Alzheimer's disease: A systematic review},
  journal = {Brain and Behavior},
  year = {2024},
  volume = {14},
  number = {6},
  doi = {10.1002/brb3.3592}
}
Kostenlos starten →